Key facts
- Dermavision Solutions’s last known valuation is $2.8M (Sep 2022).
- It has raised $1.5M; the latest was Early Stage VC ($820K) in Jul 2025.
- Notable investors include ACCIÓ, EIT Health, Josep Malvehy.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Dermavision Solutions
- ·The full record, as it builds
Funding rounds
No funding rounds for Dermavision Solutions are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dermavision Solutions
Developer of a medical device designed to detect melanoma in individuals at an early stage. The company offers artificial intelligence (AI) tools to make a diagnosis swift without the need to collect data manually by taking standardized images of patients contributing to the early detection of skin lesions, enabling healthcare professionals to get a device for gathering both clinical and meatoscopic images automatically in a single procedure.
- Sector
- Healthcare
- HQ
- Girona, Spain
- Founded
- 2019
- Employees
- 10
- Website
- dermavisions.com/
- Ownership
- Privately Held (backing)
Dermavision Solutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dermavision Solutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dermavision Solutions in its N-PORT filings yet. We sweep new filings monthly.